Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Nuformix PLC    LVRT   GB00BYW79Y38

NUFORMIX PLC (LVRT)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/15 05:35:07 pm
4 GBp   +33.33%
09/22 LEVRETT : 22/09/17 – Report and Financial Statements For the Y..
2016 LEVRETT : In "Advanced" Stages Of Nuformix Acquisition
 SummaryQuotesChartsNewsCompany 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
12/11/2017 12/12/2017 12/13/2017 12/14/2017 12/15/2017 Date
2.25(c) 2.875(c) 3(c) 3(c) 4(c) Last
4 145 318 4 858 797 5 090 164 1 830 085 35 037 796 Volume
+20.00% +27.78% +4.35% 0.00% +33.33% Change
More quotes
Company
Levrett Plc is a special purpose acquisition company.It is formed to acquire realizable and/or developed commercial technologies focused in the pharmaceutical and biotechnology sector.The company was founded on June 10, 2015 and is headquartered in London, the United Kingdom. 
More about the company
Latest news on NUFORMIX PLC
10/26 NUFORMIX : Quotient Clinical Signs Agreement with Nuformix to Evaluate Cocrystal..
10/20 LEVRETT : Quotient Clinical Signs Cocrystal Agreement with Nuformix
10/17 LEVRETT PLC : Acquires Pharmaceutical Company Nuformix
09/22 LEVRETT : 22/09/17 – Report and Financial Statements For the Year Ended 31..
2016 LEVRETT : In "Advanced" Stages Of Nuformix Acquisition
More news
Sector news : Bio Therapeutic Drugs
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15DJALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
12/13 France's Sanofi pins hopes on new drugs after setbacks
12/12 Sanofi investors hungry for drug progress and deal news
12/09 Tax-loss selling to pressure 2017's losers in December
More sector news : Bio Therapeutic Drugs
Chart NUFORMIX PLC
Duration : Period :
Nuformix PLC Technical Analysis Chart | LVRT | GB00BYW79Y38 | 4-Traders
Technical analysis trends NUFORMIX PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Managers
NameTitle
Anthony Henry Reeves Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NUFORMIX PLC0.00%0
GILEAD SCIENCES6.94%98 689
REGENERON PHARMACEUTICALS5.33%41 789
VERTEX PHARMACEUTICALS96.55%36 888
GENMAB-11.85%9 967
BLUEBIRD BIO INC199.68%8 385